Development of a time-resolved fluorescence immunoassay based on immunomagnetic beads for gastrin-17

A sensitive lateral flow immunoassay relying on time-resolved fluorescent microspheres immune probe for determination of ceftiofur and its metabolite

Ceftiofur (CEF) is an antimicrobial agent with high efficiency and low toxicity, desfuroylceftiofur is its main metabolite, but they are also have potential harm to human health. In this study, ceftiofur was combined with carrier proteins to get artificial antigens. A specific antibody (pAb) against CEF and desfuroylceftiofur was prepared. A sensitive and rapid paper-based sensor relying on time-resolved fluorescent microspheres (TRFMs) immune probes was developed, which were time-resolved fluorescent immunochromatographic strips (TRFMs-LFIA). The concentrations of T line and C line, activated pH, antibody volume and probe volume were optimized. Quantitative limits of detection (qLODs) of TRFMs-LFIA for CEF and desfuroylceftiofur were 0.97 ng/mL and 0.41 ng/mL, respectively. And 50 % inhibiting concentrations (IC50) were 12.92 ng/mL and 12.58 ng/mL, respectively. Pretreatment procedures of real samples were simple and rapid. Detection time of TRFMs-LFIA strip was 15 min. Qualitative analysis of CEF and desfuroylceftiofur was achieved under a UV light, quantitative analysis was implemented with a fluorescent immunoassay analyzer. The average recovery rates ranged from 91.4 % to 107.7 % and corresponding coefficients of variation (CV) was 1.5%-9.7 %. Concentration levels of artificially-spiked samples were measured by TRFMs-LFIA and compared with detection results of High performance liquid chromatography (HPLC), which showed a good accordance. These results indicated that the proposed assay can provide an effective strategy for on-site detection of CEF and desfuroylceftiofur simultaneously.

Development of amplified luminescent proximity homogeneous assay for quantitation of gastrin-17

A highly sensitive and convenient amplified luminescent proximity homogeneous assay (AlphaLISA) method with high throughput and automation potential was developed for quantitation of serum Gastrin-17 (G-17) levels, which can facilitate the early diagnosis of atrophic gastritis in people at high risk of gastric cancer using a non-invasive approach. In this study, donor and acceptor beads with modified carboxyl groups on the surface were directly coupled to anti-G-17 antibodies through activation was proposed for application in the development of the new AlphaLISA, which can effectively simplify the steps and shorten the reaction time to achieve faster detection. Therefore, the G-17-AlphaLISA only needs to react for 15 min to obtain good analysis results. The proposed method has a wider detection range than commercial enzyme-linked immunosorbent assay (ELISA) kits (0.12-112.8 pmol/L > 0.5-40 pmol/L). In addition, results of G-17-AlphaLISA and ELISA had good correlation and agreement (ρ = 0.936). Importantly, the developed method may be more suitable for the large-scale screening of people at high risk for gastric cancer than traditional ELISA and provides a novel solution for other biomarkers that require accurate, highly sensitive, and high throughput detection.

Cancer risk stratification system and classification of gastritis: Perspectives

Kyoto global consensus reports that the current ICD-10 classification for gastritis is obsolete. The Kyoto classification of gastritis states that severe mucosal atrophy has a high risk of gastric cancer, while mild to moderate atrophy has a low risk. The updated Kimura-Takemoto classification of atrophic gastritis considers five histological types of multifocal corpus atrophic gastritis according to stages C2 to O3. This method of morphological diagnosis of atrophic gastritis increases sensitivity by 2.4 times for severe atrophy compared to the updated Sydney system. This advantage should be considered when stratifying the high risk of gastric cancer. The updated Kimura-Takemoto classification of atrophic gastritis should be used as a reference standard (gold standard) in studies of morpho-functional relationships to identify serological markers of atrophic gastritis with evidence-based effectiveness. The use of artificial intelligence in the serological screening of atrophic gastritis makes it possible to screen a large number of the population. During serological screening of atrophic gastritis and risk stratification of gastric cancer, it is advisable to use the Kyoto classification of gastritis with updated Kimura-Takemoto classification of atrophic gastritis.

Establishment of a time‐resolved immunoassay for acute kidney injury based on the detection of Kim‐1

Aim

Methods

Results

Conclusion